2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
81
Colonic Neoplasms
18
Neoplasm Metastasis
17
Rectal Neoplasms
14
Neoplasms
13
Stomach Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Carcinoma, Renal Cell
3
Carcinoma, Neuroendocrine
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Unresectable Metastatic Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Interventions
Injections
26
toripalimab
17
pembrolizumab
17
tislelizumab
12
Gemcitabine
8
Cisplatin
7
spartalizumab
6
atezolizumab
6
Irinotecan
6
Carboplatin
6
Paclitaxel
5
Oxaliplatin
5
Nivolumab
5
Leucovorin
5
Fluorouracil
5
camrelizumab
4
Pemetrexed
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
trastuzumab deruxtecan
3
sintilimab
3
olaparib
3
lenvatinib
3
cediranib
3
PM 01183
3
Drug Therapy
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
IFL protocol
×
Clear all
NCT05147350
2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1
Terminated
38 enrolled
17 charts